王超, 李胜强, 赵岩. 西妥昔单抗不同给药策略对RAS野生型CRC肝转移患者缓解率及MMPs、miR-106b-5p、PCAT-1、不良反应的影响. 世界华人消化杂志 2022; 30(4): 204-211 [DOI: 10.11569/wcjd.v30.i4.204]
Reader's ID:
03243987
Submitted on:
March 18, 2022, 07:44
Reader Expertise:
Reader’s expertise on the topic of the manuscript
Conflicts-of-Interest Statement:
Does the reader have a conflict of interest?
Reader Comment Standards for Published Articles:
Scientific Quality:
The overall quality of the manuscript, based on the above-listed criteria, should be evaluated and classified according to the following five categories
Language Quality:
Language quality (style, grammar, and spelling) should be evaluated and classified according to the following five categories.
Reader Comments:
本文作者就目前临床上用西妥昔单抗双周给药对发生肝转移的结直肠癌患者取得疗效, 为进一步研究西妥昔单抗双周给药（即 单周组: 首次予以400 mg/m2西妥昔单抗, 静脉滴注120 min, 后续每周予以250 mg/m2西妥昔单抗, 1周/次; 双周组: 予以500 mg/m2西妥昔单抗治疗, 每2周重复）在合适的RAS野生型结直肠癌(colorectal cancer, CRC)肝转移患者中的应用价值及安全性进行统计分析，结果显示西妥昔单抗双周给药治疗RAS野生型CRC肝转移患者缓解率、生存质量改善情况优于每周给药, 但会增加患者不良反应发生率, 实际可根据患者耐受情况选择治疗方案. 整体研究给与临床诊疗的参考价值有限。